- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.12. | Aktie von Entrada Therapeutics erreicht 52-Wochen-Hoch bei 20,5 US-Dollar | 1 | Investing.com Deutsch | ||
| 02.12. | Entrada Therapeutics stock hits 52-week high at $20.5 | 1 | Investing.com | ||
| 05.11. | Entrada Therapeutics-Aktie erreicht 52-Wochen-Hoch bei 18,22 US-Dollar | 2 | Investing.com Deutsch | ||
| 05.11. | Entrada Therapeutics, Inc.: Entrada Therapeutics Reports Third Quarter 2024 Financial Results | 79 | GlobeNewswire (Europe) | - Presented additional data from the Phase 1 clinical trial ENTR-601-44-101 and new preclinical data supporting ENTR-601-45 for DMD at 2024 World Muscle Society Annual Congress - - On track to submit... ► Artikel lesen | |
| 05.11. | Entrada Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11. | Entrada Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| ENTRADA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 19.10. | Entrada Therapeutics, Inc. (NASDAQ:TRDA) Insider Natarajan Sethuraman Sells 600 Shares | 2 | MarketBeat | ||
| 09.10. | Entrada Therapeutics Presents Data Supporting Advancement Of Duchenne Franchise | 3 | RTTNews | ||
| 09.10. | Entrada Therapeutics advances Duchenne treatment trials | 2 | Investing.com | ||
| 09.10. | Entrada Therapeutics macht Fortschritte bei Duchenne-Behandlungsstudien | 3 | Investing.com Deutsch | ||
| 09.10. | Entrada Therapeutics, Inc.: Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society | 1 | GlobeNewswire (USA) | ||
| 24.09. | Entrada Therapeutics ernennt neuen Präsidenten für Forschung und Entwicklung | 2 | Investing.com Deutsch | ||
| 24.09. | Entrada Therapeutics appoints new President of R&D | 1 | Investing.com | ||
| 24.09. | Entrada Therapeutics, Inc.: Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development | 1 | GlobeNewswire (USA) | ||
| 10.09. | Entrada Therapeutics CFO sells shares worth over $47,000 | 1 | Investing.com | ||
| 06.09. | Entrada Therapeutics, Inc.: Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program | 99 | GlobeNewswire (Europe) | - Second annual DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to achieve greater equality for those living with Duchenne - - Announced in celebration... ► Artikel lesen | |
| 20.08. | Entrada Therapeutics exec sells over $440k in company stock | 1 | Investing.com | ||
| 14.08. | Entrada Therapeutics stock retains buy rating on strong Q2 net income | 1 | Investing.com | ||
| 13.08. | Entrada Therapeutics GAAP EPS of $1.55, revenue of $94.7M | 1 | Seeking Alpha | ||
| 13.08. | Entrada Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,120 | +0,90 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,402 | +10,14 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 9,000 | -7,22 % | Ginkgo Bioworks eligible for $9.4M in partnership for bioelectronic devices | ||
| RECURSION PHARMACEUTICALS | 6,790 | +12,51 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,760 | -0,83 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,730 | 0,00 % | Oncolytics Biotech Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data | ||
| ARCTURUS THERAPEUTICS | 16,140 | +4,13 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,859 | -3,66 % | Assertio Holdings, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 17,740 | +1,95 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| SIGA TECHNOLOGIES | 5,930 | 0,00 % | SIGA Technologies Inc.: Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced | Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,340 | 0,00 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 16,400 | -0,61 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,955 | +3,84 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,510 | +3,44 % | Where Will Summit Therapeutics Be in 5 Years? | ||
| BIO-PATH | 1,175 | -6,75 % | Pre-market Movers: PainReform, CURRENC Group, Bio-Path Holdings, Abpro Corporation, KULR Technology | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green PainReform Ltd. (PRFX) is up over... ► Artikel lesen |
Das Unternehmen ENTRADA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,06 % bei einem Aktienkurs von 17,590 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENTRADA THERAPEUTICS INC finden Sie auf Wallstreet Online.
